Lakefront Biotherapeutics NV (LKFT) Fair Value & Analysis
Healthcare · US · Market cap $1.9B
Lakefront Biotherapeutics NV
LKFT · US
Fair value as of: Jun 25, 2026
From 15 valuation models · updated 5 days ago
Fair value updated Jun 25, 2026 — revised from $110.68 to $110.85 (+0.2%) since Jun 24, 2026. Share price +5.7% over the past month.
Price vs Fair Value (12 months)
12‑month range $25.78 – $36.45 · fair‑value band $83.13 – $152.29 · the $29.05 price screens below the $110.85 fair value. As of Jun 25, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
Lakefront Biotherapeutics NV (LKFT) currently trades at $29.05, while our model-based Fair Value estimate is $110.85 — implying the stock looks roughly 281.6% undervalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, Lakefront Biotherapeutics NV generated revenue of $1.0B at a net margin of 46.8%. It earns a return on equity of 16.3%. The balance sheet holds a net cash position of $81.0M. The stock trades on a trailing P/E of 3.3. Fundamentals as of Jun 25, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 25, 2026. TTM = trailing twelve months.
About the company
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Lakefront Biotherapeutics NV reported revenue of $1.1B in FY2025 versus $241M in FY2022, a compound +66.4%/yr. Reported net income was $321M in FY2025.
Open the full interactive analysis →
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$562.61 | R$385.38 | -32% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Lakefront Biotherapeutics NV (LKFT) undervalued?
What is the fair value of LKFT?
What is the quality score of LKFT?
What is the revenue of Lakefront Biotherapeutics NV (LKFT)?
What is the net profit margin of LKFT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.